EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR‐mutant non–small‐cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype that contributes to the immune escape o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiiya, Akihiko, Noguchi, Takuro, Tomaru, Utano, Ariga, Shin, Takashima, Yuta, Ohhara, Yoshihito, Taguchi, Jun, Takeuchi, Satoshi, Shimizu, Yasushi, Kinoshita, Ichiro, Koizumi, Tomonobu, Matsuno, Yoshihiro, Shinagawa, Naofumi, Sakakibara‐Konishi, Jun, Dosaka‐Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067399/
https://www.ncbi.nlm.nih.gov/pubmed/36529523
http://dx.doi.org/10.1111/cas.15701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067399/
https://www.ncbi.nlm.nih.gov/pubmed/36529523
http://dx.doi.org/10.1111/cas.15701

Ejemplares similares